Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: Pooled data from randomised, double-blind, placebo-controlled studies

Human Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 103-115

  Meulien, Didier ^a   Huizar, Karin ^a   Brecher, Martin ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Extended release quetiapine fumarate; Pooled analysis; Psychosis; Schizophrenia; Tolerability

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; LORAZEPAM; OXAZEPAM; PLACEBO; QUETIAPINE;

ADULT; AGED; AGITATION; AKATHISIA; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; DYSTONIA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; GAIT DISORDER; HEADACHE; HEART RATE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; HYPOTENSION; INSOMNIA; LETHARGY; LIBIDO; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; NAUSEA; NEUTROPENIA; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS TACHYCARDIA; SOMNOLENCE; STOMACH DISCOMFORT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; XEROSTOMIA;

EID: 77749339858     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1091     Document Type: Article

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM IV. 1996.
2. Arvanitis LA, Miller BG. 1997. the Seroquel Trial 13 study group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-246.
3. Ascher-Svanum H, Faries DE, Zhu B, et al. 2006. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67: 453-460.
4. Borison RL, Arvanitis LA, Miller BG. 1996. the US Seroquel Study Group. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-169.
5. Brecher M, Leong R, Stening G, Osterling-Koskinen L, Jones AM. 2007. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 68: 597-603.
6. Cheer SM, Wagstaff AJ. 2004. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs 18: 173-199.
7. Citrome L, Volavka J. 2004. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 116: 49-49. 63.
8. Csernansky JG, Schuchart EK. 2002. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 16: 473-484.
9. De Nayer A,Windhager E, Irmansyah et al. 2003. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 7: 59-66.
10. Emsley R, Oosthuizen P. 2003. The new and evolving pharmacotherapy of schizophrenia. Psychiatr Clin North Am 26: 141-163.
11. Fleischhacker WW, Oehl MA, Hummer M. 2003. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 16 (64 Suppl): 10-13.
12. Ganesan S, Agambaram V, Randeree F, et al. 2007. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res 23: 1-12.
13. Goldstein J, Paulsson B, Sweitzer D, Zhong K. 2005. A review of the evidence for somnolence with quetiapine treatment. Poster NR 259 presented at the 158th Annual Meeting of the American Psychiatric Association, Atlanta, GA, USA, 21-26 May.
14. Kahn RS, Schulz SC, Palazov VD, et al. 2007. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 832-842.
15. Kane JM. 1996. Schizophrenia. N Engl J Med 334: 34-41.
16. Kay SR, Fiszbein A, Opler LA. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
17. Keith SJ, Kane JM. 2003. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64: 1308-1315.
18. Leucht S, Heres S. 2006. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry 67 (Suppl 5): 3-8.
19. Lindenmayer JP, Brown D, Liu S, et al. 2008. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull 41: 11-35.
20. Möller H, Johnson S, Mateva T, et al. 2008. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol 23: 95-105.
21. Montross LP, Zisook S, Kasckow J. 2005. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry 17: 173-182.
22. Osterberg L, Blaschke T. 2005. Adherence to medication. N Engl J Med 353: 487-497.
23. Peuskens J, Trivedi JK, Malyarov S, et al. 2007. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry 4: 34-50.
24. Purdon SE, Malla A, Labelle A, LitW. 2001. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137-149.
25. Rettenbacher MA, Hofer A, Eder U, et al. 2004. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 65: 1211-1218.
26. Robinson D, Woerner MG, Alvir JM, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56: 241-247.
27. Sajatovic M, Mullen JA, Sweitzer DE. 2002. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 63: 1156-1163.
28. Sax KW, Strakowski SM. 1998. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr Res 33: 151-155.
29. Small JG, Hirsch SR, Arvanitis LA, et al. 1997. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54: 549-557.
30. Velligan DI, Newcomer J, Pultz J, et al. 2002. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53: 239-248.
31. Velligan DI, Prihoda TJ, Sui D, et al. 2003. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 64: 524-531.
32. Weiden PJ, Kozma C, Grogg A, Locklear J. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 55: 886-891.